It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024. Celcuity, which is currently in a pure research and development ...

Celcuity Inc. beats earnings expectations. Reported EPS is $-0.97, expectations were $-1.06. Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year ...

The cancer-focused biotech published its final set of figures for 2025.

Celcuity, which is currently in a pure research and development phase, did not report any revenue for either the fourth quarter or the full-year 2025. During the quarter, its operating expenses ...

Celcuity, a biotechnology company focused on developing innovative treatments for various types of cancer, has made significant strides in its mission to revolutionize the field of oncology. In a ...

This trial involves a gedatolisib-based triplet treatment for second-line PIK3CA-mutant metastatic breast cancer patients. These recent developments highlight Celcuity’s ongoing progress and potential ...

The trial evaluates a gedatolisib-based triplet with palbociclib and fulvestrant in second-line PIK3CA-mutant metastatic breast cancer patients. Celcuity plans to preserve granular data details for a ...